Hallway Conversation: Perampanel

MARCH 20, 2012
In this podcast, part of Epilepsy.com’s Hallway Conversations series, Joseph Sirven, MD, professor of neurology at Mayo Clinic Arizona and editor-in-chief of Epilepsy.com, interviews Gregory Krauss, MD, professor of neurology at Johns Hopkins Medical School, about the promising new antiepileptic drug (AED) perampanel.
 
Dr. Krauss explains that perampanel, the first drug in its class fully developed to treat epilepsy, targets the AMPA receptor, 1 of 3 receptors that help control neuronal excitability of the sort involved in seizure generation. He adds that the drug has a long half life of 70 hours, which means that it only has to be taken once a day. In addition, he notes that perampanel, which has not yet been approved by the FDA, has shown great promise in treating refractory epilepsy, although there have been some variations in trial results, particularly from centers where data may not have been accurately recorded.
 
To listen to the podcast, click here and scroll down to the October 24, 2011, episode.

SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.